Interaction of Shiga toxin 2 with complement regulators of the factor H protein family

•Role of complement regulatory proteins in the pathogenesis of Stx-associated HUS.•Shiga toxin 2 (Stx2) binds to the factor H (FH) family proteins FHR-1 and FHL-1.•FHR-1 binds to Stx2 via its C-terminal region (SCRs 3–5).•FHR-1 competes with FH for Stx2 binding leading to reduced cofactor activity o...

Full description

Saved in:
Bibliographic Details
Published inMolecular immunology Vol. 58; no. 1; pp. 77 - 84
Main Authors Poolpol, Kulwara, Orth-Höller, Dorothea, Speth, Cornelia, Zipfel, Peter F., Skerka, Christine, de Córdoba, Santiago Rodriguez, Brockmeyer, Jens, Bielaszewska, Martina, Würzner, Reinhard
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.03.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:•Role of complement regulatory proteins in the pathogenesis of Stx-associated HUS.•Shiga toxin 2 (Stx2) binds to the factor H (FH) family proteins FHR-1 and FHL-1.•FHR-1 binds to Stx2 via its C-terminal region (SCRs 3–5).•FHR-1 competes with FH for Stx2 binding leading to reduced cofactor activity of FH.•FHL-1 retains its cofactor activity in the fluid phase when bound to Stx2. Shiga toxin 2 (Stx2) is believed to be a major virulence factor of enterohemorrhagic Escherichia coli (EHEC) contributing to hemolytic uremic syndrome (HUS). The complement system has recently been found to be involved in the pathogenesis of EHEC-associated HUS. Stx2 was shown to activate complement via the alternative pathway, to bind factor H (FH) at short consensus repeats (SCRs) 6–8 and 18–20 and to delay and reduce FH cofactor activity on the cell surface. We now show that complement factor H-related protein 1 (FHR-1) and factor H-like protein 1 (FHL-1), proteins of the FH protein family that show amino acid sequence and regulatory function similarities with FH, also bind to Stx2. The FHR-1 binding site for Stx2 was located at SCRs 3–5 and the binding capacity of FHR-1*A allotype was higher than that of FHR-1*B. FHR-1 and FHL-1 competed with FH for Stx2 binding, and in the case of FHR-1 this competition resulted in a reduction of FH cofactor activity. FHL-1 retained its cofactor activity in the fluid phase when bound to Stx2. In conclusion, multiple interactions of key complement inhibitors FH, FHR-1 and FHL-1 with Stx2 corroborate our hypothesis of a direct role of complement in EHEC-associated HUS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0161-5890
1872-9142
DOI:10.1016/j.molimm.2013.11.009